Beskrywing

The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 27% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for autoimmune diseases treatment. The China autoimmune diseases treatment market is segmented on the basis of product, tipe. Per produk, it is categorized into biologics, and small molecule chemical drugs. The small molecule chemical drugs segment held the largest market share in 2020. Egter, the biologics segment is expected to witness the highest CAGR during the forecast period. Volgens tipe, the autoimmune diseases treatment market is divided into immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE).

The report has profiled some of the key players of the market such as UCB S.A., AbbVie Inc., GlaxoSmithKline plc., Janssen Pharmaceutica NV, Novartis International AG, Pfizer Inc., Roche Holding AG, Rongchang Pharmacy Co. Bpk..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Produk: biologics, and small molecule chemical drugs
Tik: immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE)
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China autoimmune diseases treatment market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the autoimmune diseases treatment market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Autoimmune Diseases Treatment Market by Product
4.1 Biologics
4.2 Small Molecule Chemical Drugs
5. Autoimmune Diseases Treatment Market by Type
5.1 Immunoglobulin A Nephropathy (IgAN)
5.2 Multiple Sclerosis (MS)
5.3 Myasthenia Gravis (MG)
5.4 Neuromyelitis Optica Spectrum Disorder (NMOSD)
5.5 Rheumatoid Arthritis (RA)
5.6 Sjogren’S Syndrome (SS)
5.7 Systemic Lupus Erythematosus (SLE)
6. Maatskappy profiele
6.1 UCB S.A.
6.2 AbbVie Inc.
6.3 GlaxoSmithKline plc.
6.4 Janssen Pharmaceutica NV
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Rongchang Pharmacy Co., Bpk.
7. Bylaag
7.1 Oor StrategyHelix
7.2 Vrywaring